P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients

Mark J. Krasna, You Sheng Mao, Joshua R. Sonett, Gen Tamura, Ray Jones, Mohan Suntharalingam, Stephen Meltzer

Research output: Contribution to journalArticle

Abstract

Background. P53 protein overexpression in esophageal cancer and its correlation with response and survival after chemoradiation was retrospectively investigated. Methods. Pretreatment and resection specimens were stained by automatic p53 immunohistochemical staining technique. Results. P53 was expressed in 84.0% of esophagoscopy (EGD) biopsies; 71.4% of patients with metastasis of thoracoscopy/laparoscopy lymph nodes (TS/LS LN) identified by hematoxylin/eosin (H/E) were p53 (+); 14.2% of patients with negative TS/LS LN by H/E were p53 (+). Eleven out of 18 patients with p53 (+) in pretreatment EGD remained p53 (+) after chemoradiation; 38.8% of these patients had a pathological complete response (pCR). The median survival of this group was 15 months. Of 4 patients with p53 (-) pretreatment EGD, all of those were still p53 (-) after chemoradiation; 75% of these patients had pCR. The median survival was 30 months. In patients with p53 (+) TS/LS LN, 23% had a pCR after chemoradiation with a median survival of 16 months. In patients with p53 (-) TS/LS LN, 50.0% had a pCR with a median survival of 31.5 months. Conclusions. P53 protein overexpression in pretreatment EGD and TS/LS LN may predict response to chemoradiation and survival in esophageal cancer patients.

Original languageEnglish (US)
Pages (from-to)2021-2025
Number of pages5
JournalAnnals of Thoracic Surgery
Volume68
Issue number6
DOIs
StatePublished - Dec 1999
Externally publishedYes

Fingerprint

p53 Genes
Esophageal Neoplasms
Thoracoscopy
Laparoscopy
Lymph Nodes
Proteins
Survival
Therapeutics
Hematoxylin
Eosine Yellowish-(YS)
Esophagoscopy
Staining and Labeling
Neoplasm Metastasis
Biopsy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients. / Krasna, Mark J.; Mao, You Sheng; Sonett, Joshua R.; Tamura, Gen; Jones, Ray; Suntharalingam, Mohan; Meltzer, Stephen.

In: Annals of Thoracic Surgery, Vol. 68, No. 6, 12.1999, p. 2021-2025.

Research output: Contribution to journalArticle

Krasna, Mark J. ; Mao, You Sheng ; Sonett, Joshua R. ; Tamura, Gen ; Jones, Ray ; Suntharalingam, Mohan ; Meltzer, Stephen. / P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients. In: Annals of Thoracic Surgery. 1999 ; Vol. 68, No. 6. pp. 2021-2025.
@article{b2e6761649aa48cc9d49c1edf0e4de15,
title = "P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients",
abstract = "Background. P53 protein overexpression in esophageal cancer and its correlation with response and survival after chemoradiation was retrospectively investigated. Methods. Pretreatment and resection specimens were stained by automatic p53 immunohistochemical staining technique. Results. P53 was expressed in 84.0{\%} of esophagoscopy (EGD) biopsies; 71.4{\%} of patients with metastasis of thoracoscopy/laparoscopy lymph nodes (TS/LS LN) identified by hematoxylin/eosin (H/E) were p53 (+); 14.2{\%} of patients with negative TS/LS LN by H/E were p53 (+). Eleven out of 18 patients with p53 (+) in pretreatment EGD remained p53 (+) after chemoradiation; 38.8{\%} of these patients had a pathological complete response (pCR). The median survival of this group was 15 months. Of 4 patients with p53 (-) pretreatment EGD, all of those were still p53 (-) after chemoradiation; 75{\%} of these patients had pCR. The median survival was 30 months. In patients with p53 (+) TS/LS LN, 23{\%} had a pCR after chemoradiation with a median survival of 16 months. In patients with p53 (-) TS/LS LN, 50.0{\%} had a pCR with a median survival of 31.5 months. Conclusions. P53 protein overexpression in pretreatment EGD and TS/LS LN may predict response to chemoradiation and survival in esophageal cancer patients.",
author = "Krasna, {Mark J.} and Mao, {You Sheng} and Sonett, {Joshua R.} and Gen Tamura and Ray Jones and Mohan Suntharalingam and Stephen Meltzer",
year = "1999",
month = "12",
doi = "10.1016/S0003-4975(99)01146-7",
language = "English (US)",
volume = "68",
pages = "2021--2025",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients

AU - Krasna, Mark J.

AU - Mao, You Sheng

AU - Sonett, Joshua R.

AU - Tamura, Gen

AU - Jones, Ray

AU - Suntharalingam, Mohan

AU - Meltzer, Stephen

PY - 1999/12

Y1 - 1999/12

N2 - Background. P53 protein overexpression in esophageal cancer and its correlation with response and survival after chemoradiation was retrospectively investigated. Methods. Pretreatment and resection specimens were stained by automatic p53 immunohistochemical staining technique. Results. P53 was expressed in 84.0% of esophagoscopy (EGD) biopsies; 71.4% of patients with metastasis of thoracoscopy/laparoscopy lymph nodes (TS/LS LN) identified by hematoxylin/eosin (H/E) were p53 (+); 14.2% of patients with negative TS/LS LN by H/E were p53 (+). Eleven out of 18 patients with p53 (+) in pretreatment EGD remained p53 (+) after chemoradiation; 38.8% of these patients had a pathological complete response (pCR). The median survival of this group was 15 months. Of 4 patients with p53 (-) pretreatment EGD, all of those were still p53 (-) after chemoradiation; 75% of these patients had pCR. The median survival was 30 months. In patients with p53 (+) TS/LS LN, 23% had a pCR after chemoradiation with a median survival of 16 months. In patients with p53 (-) TS/LS LN, 50.0% had a pCR with a median survival of 31.5 months. Conclusions. P53 protein overexpression in pretreatment EGD and TS/LS LN may predict response to chemoradiation and survival in esophageal cancer patients.

AB - Background. P53 protein overexpression in esophageal cancer and its correlation with response and survival after chemoradiation was retrospectively investigated. Methods. Pretreatment and resection specimens were stained by automatic p53 immunohistochemical staining technique. Results. P53 was expressed in 84.0% of esophagoscopy (EGD) biopsies; 71.4% of patients with metastasis of thoracoscopy/laparoscopy lymph nodes (TS/LS LN) identified by hematoxylin/eosin (H/E) were p53 (+); 14.2% of patients with negative TS/LS LN by H/E were p53 (+). Eleven out of 18 patients with p53 (+) in pretreatment EGD remained p53 (+) after chemoradiation; 38.8% of these patients had a pathological complete response (pCR). The median survival of this group was 15 months. Of 4 patients with p53 (-) pretreatment EGD, all of those were still p53 (-) after chemoradiation; 75% of these patients had pCR. The median survival was 30 months. In patients with p53 (+) TS/LS LN, 23% had a pCR after chemoradiation with a median survival of 16 months. In patients with p53 (-) TS/LS LN, 50.0% had a pCR with a median survival of 31.5 months. Conclusions. P53 protein overexpression in pretreatment EGD and TS/LS LN may predict response to chemoradiation and survival in esophageal cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0343049069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343049069&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(99)01146-7

DO - 10.1016/S0003-4975(99)01146-7

M3 - Article

C2 - 10616970

AN - SCOPUS:0343049069

VL - 68

SP - 2021

EP - 2025

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -